Carmichael Hill & Associates, Inc. Brooklyn Immuno Therapeutics, Inc. Call Options Transaction History

Carmichael Hill & Associates, Inc.

  • $279 Million
  • Q3 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding BTX

# of Institutions
1
Shares Held
1.21M
Call Options Held
0
Put Options Held
0
View Full List

About Brooklyn ImmunoTherapeutics, Inc.

BTX Quotes by TradingView
  • Ticker BTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,825,700
  • Description
  • Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy techno...
More about BTX
Track This Portfolio

Track Carmichael Hill & Associates, Inc. Portfolio

Follow Carmichael Hill & Associates, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Carmichael Hill & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Carmichael Hill & Associates, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email